AXP Share Price

Open 114.65 Change Price %
High 114.65 1 Day -1.55 -1.33
Low 114.65 1 Week 3.05 2.73
Close 114.65 1 Month 3.35 3.01
Volume 125 1 Year -2.65 -2.26
52 Week High 136.65
52 Week Low 86.80
AXP Important Levels
Resistance 2 114.65
Resistance 1 114.65
Pivot 114.65
Support 1 114.65
Support 2 114.65
ETR Germany Most Active Stocks
DBK 14.10 -0.07%
DBK 14.10 -0.07%
CBK 10.94 0.55%
CBK 10.94 0.55%
EOAN 9.62 0.21%
EOAN 9.62 0.21%
DTE 15.51 -0.32%
DTE 15.51 -0.32%
DTE 15.51 -0.32%
DTE 15.51 -0.32%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
5M71 39.00 13.70%
SAZ 72.55 13.18%
BEO 3.38 6.96%
QS5 512.25 6.66%
NXU 25.36 6.55%
CEA 19.96 6.40%
CEA 19.96 6.40%
PCR 8.15 5.57%
PCR 8.15 5.57%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
NK2A 0.08 -11.11%
DOQ 55.55 -9.39%
BDT 77.25 -7.78%
DCO 99.45 -6.88%
DCO 99.45 -6.88%
More..

Alexion Pharmaceuticals Inc (ETR: AXP)

AXP Technical Analysis 2
As on 18th Aug 2017 AXP Share Price closed @ 114.65 and we RECOMMEND Sell for LONG-TERM with Stoploss of 116.26 & Strong Buy for SHORT-TERM with Stoploss of 107.66 we also expect STOCK to react on Following IMPORTANT LEVELS.
AXP Target for August
1st Target up-side 124.92
2nd Target up-side 130.57
3rd Target up-side 136.22
1st Target down-side 108.78
2nd Target down-side 103.13
3rd Target down-side 97.48
AXP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.alexionpharm.com
AXP Address
AXP
352 Knotter Drive
Cheshire, CT 06410
United States
Phone: 203-272-2596
Fax: 203-271-8198
AXP Latest News
Interactive Technical Analysis Chart Alexion Pharmaceuticals Inc ( AXP ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Alexion Pharmaceuticals Inc
AXP Business Profile
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.